Torrent Pharmaceuticals Limited , a leading Indian pharmaceutical company, has announced robust financial results for the first quarter, showcasing significant growth across key markets and improved profitability.

Financial Highlights

• Revenue increased by 11% year-over-year to Rs 3,178.00 crore
• Net profit surged by 20% to Rs 548.00 crore
• Operating EBITDA grew by 14% to Rs 1,032.00 crore
• EBITDA margin improved to 32.50%
• Gross margin remained steady at 76.00%

Market Performance

India

The company's performance in its home market remained strong:

• India revenues rose by 11% to Rs 1,811.00 crore
• Chronic business grew by 13%, outpacing the Indian Pharmaceutical Market (IPM) growth of 9%
• 21 brands featured in the Top 500 IPM brands, with 14 brands generating over Rs 100.00 crore in sales

Brazil

Torrent Pharma continued to make strides in the Brazilian market:

• Brazil revenues increased by 11% to Rs 218.00 crore
• Constant currency revenues grew by 16% to R$ 143.00 million
• The company outperformed the market, growing at 14% compared to the overall market growth of 5%
• 62 products are currently under review by ANVISA, the Brazilian health regulatory agency

Germany

Despite challenges, the German business showed resilience:

• Germany revenues grew by 9% to Rs 308.00 crore
• Constant currency revenues increased by 1% to EUR 32.00 million
• Growth was impacted by supply disruptions from a third-party supplier

United States

The US market demonstrated strong growth:

• US revenues surged by 19% to Rs 308.00 crore
• Constant currency revenues increased by 16% to $36.00 million
• Recent product launches have achieved targeted market shares

R&D Investment

Torrent Pharma continued to invest in research and development:

• R&D spend increased by 16% to Rs 157.00 crore, representing 5% of total revenues

Future Outlook

Torrent Pharmaceuticals is poised for further growth with its strong presence in both domestic and international markets. The company's robust pipeline of products under review in Brazil and its recent successful launches in the US market indicate potential for continued expansion.

As Torrent Pharma maintains its position as the 7th ranked company in the Indian Pharmaceutical Market and continues to be among the top 5 in key therapeutic segments, it is well-positioned to capitalize on growth opportunities in the pharmaceutical sector.

With its strong financial performance, continued focus on key therapeutic areas, and expansion in international markets, Torrent Pharmaceuticals Limited demonstrates resilience and growth potential in the competitive pharmaceutical industry.

Torrent Pharmaceuticals Limited , one of India's leading pharmaceutical companies, has announced robust financial results for the first quarter of fiscal year 2026, demonstrating strong growth across its key markets.

Financial Highlights

Market Performance

India

• India revenues rose by 11% to Rs. 1,811.00 crores, outperforming the Indian Pharmaceutical Market (IPM) growth of 8%
• Chronic business grew by 13%, compared to the IPM growth of 9% in this segment
• The company now has 21 brands in the Top 500 IPM brands, with 14 brands generating over Rs. 100.00 crores in sales

Brazil

• Brazil revenues increased by 11% to Rs. 218.00 crores
• In constant currency terms, revenues grew by 16% to R$ 143.00 million
• Torrent Pharmaceuticals outperformed the market with 14% growth compared to overall market growth of 5%
• Growth was driven by strong performance of top brands and new product launches
• The company has 62 products under review by ANVISA, Brazil's health regulatory agency

Germany

• Germany revenues grew by 9% to Rs. 308.00 crores
• Constant currency revenues increased by 1% to EUR 32.00 million
• Growth was impacted by supply disruptions from a third-party manufacturer

United States

• US business revenues surged by 19% to Rs. 308.00 crores
• Constant currency revenues grew by 16% to $36.00 million
• Recent product launches have achieved their targeted market shares

R&D and Future Outlook

Torrent Pharmaceuticals continues to invest in research and development, with R&D spend increasing by 16% to Rs. 157.00 crores, representing 5% of total revenues. This investment underscores the company's commitment to innovation and future growth.

Management Commentary

Samir Mehta, Executive Chairman of Torrent Pharmaceuticals Limited, commented on the results, stating, "We are pleased with our strong start to FY26, with robust growth across our key markets. Our focus on chronic therapies and strategic launches has paid off, particularly in India and Brazil. While we face some challenges in Germany due to supply disruptions, we are working to address these issues. Our U.S. business continues to show promising growth, and we remain committed to expanding our presence in this important market."

Conclusion

Torrent Pharmaceuticals' Q1 FY26 results demonstrate the company's resilience and strong market position. With a diverse geographical presence, focus on chronic therapies, and continued investment in R&D, Torrent Pharmaceuticals is well-positioned for sustained growth in the coming quarters.